MCID: CTN015
MIFTS: 38

Cutaneous T Cell Lymphoma malady

Categories: Rare diseases, Cancer diseases, Immune diseases, Skin diseases, Blood diseases

Aliases & Classifications for Cutaneous T Cell Lymphoma

About this section

Aliases & Descriptions for Cutaneous T Cell Lymphoma:

Name: Cutaneous T Cell Lymphoma 10 12
Lymphoma, T-Cell, Cutaneous 65
Cutaneous T-Cell Lymphoma 45
 
Lymphoma T-Cell Cutaneous 47
Ctcl 45

Classifications:



External Ids:

Disease Ontology10 DOID:0060061
UMLS65 C0079773

Summaries for Cutaneous T Cell Lymphoma

About this section
NIH Rare Diseases:45 Cutaneous t-cell lymphomas (ctcls) are a group of disorders characterized by an abnormal accumulation of cancerous t-cells (a type of white blood cells) in the skin resulting in an itchy, red rash that can thicken or form a tumor. ctcls belong to a larger group of disorders known asnon-hodgkin's lymphomas. the most common types are mycosis fungoides and sézary syndrome. in some cases, cancerous t-cells may spread to the lymph nodes and eventually to other body tissues and organs, potentially resulting in life-threatening complications. the specific signs and symptoms vary from person to person. the exact cause of these conditions is unknown. last updated: 9/27/2011

MalaCards based summary: Cutaneous T Cell Lymphoma, also known as lymphoma, t-cell, cutaneous, is related to alpha 1-antitrypsin deficiency and chronic eosinophilic pneumonia. An important gene associated with Cutaneous T Cell Lymphoma is CTAGE1 (Cutaneous T-Cell Lymphoma-Associated Antigen 1), and among its related pathways are Downstream signaling in naive CD8+ T cells and Inflammatory Response Pathway. The drugs bexarotene and denileukin have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related mouse phenotypes are hematopoietic system and immune system.

Disease Ontology:10 A non-Hodgkin's lymphoma that is caused by a mutation of T cells.

Related Diseases for Cutaneous T Cell Lymphoma

About this section

Diseases in the Cutaneous T Cell Lymphoma family:

Primary Cutaneous Gamma/delta-Positive T-Cell Lymphoma

Diseases related to Cutaneous T Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 539)
idRelated DiseaseScoreTop Affiliating Genes
1alpha 1-antitrypsin deficiency29.9HDAC9, IL2, IL2RA
2chronic eosinophilic pneumonia29.7IFNA1, IFNA2, IL15, IL2
3hypoglycemia29.7IFNG, IL2, STAT3
4viral hepatitis29.4IFNA1, IFNA2, IFNG, STAT3
5urethral diverticulum29.0IFNA1, IFNA2, IFNG, IL15, IL2
6mycosis fungoides10.8
7sezary's disease10.8
8endotheliitis10.6
9parapsoriasis10.5
10granulomatous slack skin disease10.5
11hepatitis10.5
12neuronitis10.5
13lysosomal storage disease10.4IFNA1, IFNA2
14chancroid10.4IFNA1, IFNA2
15lymphoma10.4
16subareolar duct papillomatosis10.4IFNA1, IFNA2
17breast cancer10.4
18leukemia10.4
19prostatitis10.4
20thyroiditis10.4
21atherosclerosis10.3
22sarcoma10.3
23retinitis10.3
24autoimmune gastrointestinal dysmotility10.3IL2RA, STAT3
25melanoma10.3
26ischemia10.3
27psoriasis10.3
28hypoxia10.3
29colorectal cancer10.3
30prostate cancer10.3
31coronary artery disease10.3
32arthritis10.3
33hepatitis b10.3
34liver disease10.3
35retinitis pigmentosa10.3
36thrombocytopenia10.3
37artery disease10.3
38hepatitis c10.3
39cerebritis10.3
40glioma10.3
41maculopapular lupus rash10.2IFNA1, IFNA2
42skin epithelioid hemangioma10.2ADA, IL2
43urinary bladder small cell neuroendocrine carcinoma10.2ADA, IFNA2, IL2RA
44rheumatoid arthritis10.2
45myocardial infarction10.2
46lung cancer10.2
47asthma10.2
48cholangiocarcinoma10.2
49gastric cancer10.2
50glomerulonephritis10.2

Graphical network of the top 20 diseases related to Cutaneous T Cell Lymphoma:



Diseases related to cutaneous t cell lymphoma

Symptoms for Cutaneous T Cell Lymphoma

About this section

Drugs & Therapeutics for Cutaneous T Cell Lymphoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Istodax15 41 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
FDA Label: Istodax
Disease/s that Drug Treats:cutaneous T-cell lymphoma
Indications and Usage:15 ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for: Treatment of cutaneous T-cell lymphoma (CTCL) in patients who havereceived at least one prior systemic therapy (1). Treatment of peripheral T-cell lymphoma (PTCL) in patients who havereceived at least one prior therapy (1).These indications are based on response rate. Clinical benefit such asimprovement in overall survival has not been demonstrated (1).
DrugBank Targets:13 -
Mechanism of Action:15 
Target: histone deacetylase (HDAC)
Action: inhibitor
FDA: Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in themodulation of gene expression. HDACs also deacetylate non-histone proteins, such as transcription factors. In vitro, romidepsin causes the accumulation of acetylatedhistones, and induces cell cycle arrest and apoptosis of some cancer cell lines with IC50 values in the nanomolar range. The mechanism of the antineoplastic effect ofromidepsin observed in nonclinical and clinical studies has not been fully characterized.
2
Targretin 15 41 bexarotene VALEANT LUXEMBOURG 12/29/1999
FDA Label: Targretin
Disease/s that Drug Treats:cutaneous T-cell lymphoma
Indications and Usage:15 TARGRETIN (bexarotene) is a retinoid indicated for the treatment ofcutaneous manifestations of cutaneous T-cell lymphoma in patients who arerefractory to at least one prior systemic therapy. (1)
DrugBank Targets:13 1. Retinoic acid receptor RXR-alpha;2. Retinoic acid receptor RXR-beta;3. Retinoic acid receptor RXR-gamma
Mechanism of Action:15 
Target: retinoid X receptor subtypes (RXRalpha, RXRbeta, RXRgama)
Action: activator
FDA: Bexarotene selectively binds and activates retinoid X receptor subtypes (RXR, RXR, RXR).RXRs can form heterodimers with various receptor partners such as retinoic acid receptors (RARs),vitamin D receptor, thyroid receptor, and peroxisome proliferator activator receptors (PPARs). Onceactivated, these receptors function as transcription factors that regulate the expression of genes thatcontrol cellular differentiation and proliferation. Bexarotene inhibits the growth in vitro of sometumor cell lines of hematopoietic and squamous cell origin. It also induces tumor regression in vivoin some animal models. The exact mechanism of action of bexarotene in the treatment of cutaneousT-cell lymphoma (CTCL) is unknown.
3
UVADEX15 METHOXSALEN Therakos February 1999
FDA Label: UVADEX
Disease/s that Drug Treats:skin manifestations of cutaneous T-cell lymphoma (CTCL)
Indications and Usage:15 UVADEX™ (methoxsalen) Sterile Solution is indicated for extracorporeal administration withthe UVAR™ XTS™ or THERAKOS™ CELLEX™ Photopheresis System in the palliativetreatment of the skin manifestations of Cutaneous T-Cell Lymphoma (CTCL) that isunresponsive to other forms of treatment.
DrugBank Targets:13 1. DNA
Mechanism of Action:15 
Target: DNA
Action: inhibitor of DNA synthesis, cell division, and epidermal turnover
FDA: The exact mechanism of action of methoxsalen is not known. The best-known biochemicalreaction of methoxsalen is with DNA. Methoxsalen, upon photoactivation, conjugates and formscovalent bonds with DNA which leads to the formation of both monofunctional (addition to asingle strand of DNA) and bifunctional adducts (crosslinking of psoralen to both strands ofDNA). Reactions with proteins have also been described. The formation of photoadducts resultsin inhibition of DNA synthesis, cell division and epidermal turnover.For the palliative treatment of Cutaneous T-Cell Lymphoma, Photopheresis consists of removinga portion of the patient's blood and separating the red blood cells from the white cell layer (buffycoat) by centrifugation. The red cells are returned to the patient and the UVADEX™ SterileSolution is then injected into the instrument and mixed with the buffy coat. The instrument thenirradiates this drug-cell mixture with ultraviolet light (UVA light, 320-400 nm) and returns thetreated cells to the patient. See the appropriate Operator's Manual for details of this process.Although extracorporeal phototherapy exposes less than 10% of the total body burden ofmalignant cells to methoxsalen plus light, some patients achieve a complete response. Animalstudies suggest that the photopheresis may activate an immune-mediated response against themalignant T-cells.Use of the UVAR™ and UVAR™ XTS™ Systems after oral administration of methoxsalenwere previously approved for the treatment of Cutaneous T-Cell Lymphoma. Interpatientvariability in peak plasma concentration after an oral dose of methoxsalen ranges from 6 to 15fold. UVADEX™ is injected directly into the separated buffy coat in the instrument in anattempt to diminish this interpatient variability and to improve the exposure of the cells to thedrug.Methoxsalen is reversibly bound to serum albumin and is also preferentially taken up byepidermal cells. Methoxsalen is rapidly metabolized in humans, with approximately 95% of thedrug excreted as metabolites in the urine within 24 hours.Systemic administration of methoxsalen followed by UVA exposure leads to cell injury. Themost obvious manifestation of this injury after skin exposure is delayed erythema, which maynot begin for several hours and peaks at 48-72 hours. The inflammation is followed over severaldays to weeks, by repair which is manifested by increased melanization of the epidermis andthickening of the stratum corneum.The total dose of methoxsalen delivered in UVADEX™ is substantially lower (approximately200 times) than that used with oral administration. More than 80% of blood samples collected30 minutes after reinfusion of the photoactivated buffy coat had methoxsalen levels belowdetection limits of the assay (<10 ng/ml), and the mean plasma methoxsalen concentration wasapproximately 25 ng/ml.
4
Valchlor15 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics August 2013
FDA Label: Valchlor
Disease/s that Drug Treats:Stage IA/IB mycosisfungoides-type cutaneous T-cell lymphoma
Indications and Usage:15 VALCHLOR is an alkylating drug indicated for the topical treatmentof Stage IA and IB mycosis fungoides‐type cutaneous T‐celllymphoma in patients who have received prior skin‐directed therapy(1).  
DrugBank Targets:13 1. DNA
Mechanism of Action:15 
Target: rapidly-proliferating cells
Action: inhibitor
FDA: Mechlorethamine, also known as nitrogen mustard, is an alkylating agent which inhibits rapidly proliferating cells.

Drugs for Cutaneous T Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 398)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
MethotrexateapprovedPhase 4, Phase 3, Phase 2, Phase 114441959-05-2, 59-05-2126941
Synonyms:
4-amino-10-methylfolic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Emtexate
Folex
HDMTX
L-Amethopterin
Ledertrexate
MTX
Metatrexan
Methopterin
Methotextrate
 
Methotrate
Methotrexat
Methotrexate
Methotrexate Sodium
Methotrexatum
Methylaminopterin
Methylaminopterinum
Metoject
Metotrexato
Mexate
Méthotrexate
N-Bismethylpteroylglutamic Acid
N-[4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
Otrexup
Rasuvo
Rheumatrex
Rheumatrex Dose Pack
Trexall
2
Aprepitantapproved, investigationalPhase 4154170729-80-3151165, 6918365
Synonyms:
170729-80-3
221350-96-5
3-(((2R,3S)-3-(P-Fluorophenyl)-2-(((alphar)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one
5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one
5-[[(2S,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one
5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
AC1L45SL
AC1OCFCG
Aprepitant
Aprepitant (JAN/USAN/INN)
Aprepitant [USAN]
Aprepitantum
Aprépitant
CHEBI:323967
CHEBI:499361
CHEMBL135613
CHEMBL1471
CHEMBL249465
CID11214788
CID11318675
 
CID151165
CID6918365
CID9936947
CID9936948
D02968
DB00673
Emend
Emend (TN)
HMS2090N12
I06-1151
L 754030
L-754030
LS-156477
MK 0869
MK 869
MK-0517
MK-0869
MK-869
MK-869, L-754030, Emend, Aprepitant
MolPort-006-392-367
NCGC00181785-01
ONO-7436
S1189_Selleck
UNII-1NF15YR6UY
3
Vorinostatapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1238149647-78-95311
Synonyms:
149647-78-9
1zz1
AC-1923
AC1L1K2K
BRD-K81418486-001-10-3
C111237
CCRIS 8456
CHEBI:45716
CHEMBL98
CID5311
D06320
DB02546
EC-000.2057
FT-0082592
LS-186548
LS-186997
LS-187780
MK-0683
MK0683
MLS001065855
Merck brand of Vorinostat
MolPort-003-850-293
N'-hydroxy-N-phenyloctanediamide
N-Hydroxy-N'-phenyl octanediamide
N-Hydroxy-N'-phenyloctanediamide
N-Hyrdroxy-N'-phenyloctanediamide
N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide
N-hydroxy-N'-phenyloctanediamide
N1-hydroxy-N8-phenyloctanediamide
NCGC00168085-02
 
NHNPODA
NSC-701852
NSC701852
OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE
Octanedioic acid hydroxyamide phenylamide
S1047_Selleck
SAHA
SAHA cpd
SAHA, Suberoylanilide hydroxamic acid
SHH
SKI390
SMR000486344
SW-064652
Suberanilohydroxamic acid
SuberoylaN/Aide hydroxamic acid
Suberoylanilide hydroxamic acid
UNII-58IFB293JI
Vorinostat
Vorinostat (JAN/USAN)
Vorinostat MSD
Vorinostat [USAN]
Vorinostatum
WIN64652
ZINC01543873
Zolinza
Zolinza (TN)
Zolinza, MK-0683, SAHA
m344
nchembio.275-comp2
nchembio.313-comp1
nchembio815-comp18
suberoylanilide hydroxamic acid
4
MethoxsalenapprovedPhase 4, Phase 3, Phase 2, Phase 134298-81-74114
Synonyms:
12692-94-3
298-81-7
5-19-06-00015 (Beilstein Handbook Reference)
5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone
5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone
6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone
7-Furocoumarin
8 MOP
8 Methoxypsoralen
8-METHOXYPSORALEN + UVA (SEE ALSO C55903)
8-MOP
8-MP
8-Methoxy
8-Methoxy(furano-3'.2':6.7-coumarin)
8-Methoxy-(furano-3'.2':6.7-coumarin)
8-Methoxy-2',3',6,7-furocoumarin
8-Methoxy-4',5',6,7-furocoumarin
8-Methoxy-4',5':6,7-furocoumarin
8-Methoxy-[furano-3'.2':6.7-coumarin]
8-Methoxyfuranocoumarin
8-Methoxypsoralen
8-Methoxypsoralen with ultraviolet A therapy
8-Methoxypsoralene
8-methoxyfuranocoumarins
8-methoxyfurocoumarins
8-mop
8MO
8MOP
9-(methyloxy)-7H-furo[3,2-g]chromen-7-one
9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one
9-Methoxy-7H-furo(3,2-g)benzopyran-7-one
9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one
9-Methoxy-7H-furo[3,2-g]chromen-7-one
9-Methoxyfuro(3,2-g)chromen-7-one
9-Methoxyfuro[3,2-g][1]benzopyran-7-one
9-Methoxypsoralen
9-metho xy-7H-furo(3,2-g)benzopyran-7-one
9-methoxyfuro[3,2-g]chromen-7-one
A1783/0075596
AC-4259
AC1L1HFY
ACon1_000174
AKOS000277012
Ammodin
Ammoidin
BPBio1_000680
BRD-K63430059-001-03-2
BRD-K63430059-001-06-5
BRN 0196453
BSPBio_000618
BSPBio_001997
Boehringer Ingelheim Brand of Methoxsalen
C01864
CAS-298-81-7
CCRIS 2083
CHEBI:18358
CHEBI:52028
CHEMBL416
CID4114
CPD-13042
CPD000071170
Canderm Brand of Methoxsalen
Chinoin Brand of Methoxsalen
D00139
D008730
DB Brand of Methoxsalen
DB00553
Delta Brand of Methoxsalen
Deltasoralen
Dermatech Brand of Methoxsalen
Dermox
DivK1c_000763
EINECS 206-066-9
FT-0082222
Galderma Brand of Methoxsalen
Geroxalen
HMS1569O20
HMS1920N05
HMS2091D20
HMS502G05
HSDB 2505
I06-0695
ICN Brand 1 of Methoxsalen
ICN Brand 2 of Methoxsalen
ICN Brand 3 of Methoxsalen
IDI1_000763
Jsp005650
KBio1_000763
KBio2_001503
KBio2_004071
KBio2_006639
KBio3_001497
KBioGR_000543
KBioSS_001503
LS-68
M3501_FLUKA
M3501_SIAL
MEGxp0_000095
 
MLS000062633
MLS002303011
Meladinin
Meladinin (VAN)
Meladinina
Meladinine
Meladoxen
Meloxine
Methoxa Dome
Methoxa-Dome
Methoxalen
Methoxaten
Methoxsalen
Methoxsalen (JP15/USP)
Methoxsalen Canderm Brand
Methoxsalen Chinoin Brand
Methoxsalen Delta Brand
Methoxsalen Dermatech Brand
Methoxsalen Mex-America Brand
Methoxsalen Sanofi-Synthelabo Brand
Methoxsalen [BAN:JAN]
Methoxsalen plus ultraviolet radiation
Methoxsalen with ultra-violet A theraphy
Methoxy-8-psoralen
Mex America Brand of Methoxsalen
Mex-America Brand of Methoxsalen
MolPort-000-696-480
Méthoxsalène
NCGC00016418-01
NCGC00060938-02
NCGC00060938-03
NCGC00060938-04
NCGC00060938-05
NCGC00060938-06
NCGC00178871-01
NCGC00178871-02
NCGC00178871-03
NCI-C55903
NCI60_004085
NINDS_000763
NSC 45923
NSC45923
New-Meladinin
O-Methylxanthotoxol
O-methylxanthotoxol
OXSORALEN (TN)
Oprea1_166319
Oxoralen
Oxsoralen
Oxsoralen Lotion
Oxsoralen Ul tra
Oxsoralen Ultra
Oxsoralen lotion
Oxsoralen-Ultra
Oxsoralen-ultra
Oxypsoralen
Prestwick0_000479
Prestwick1_000479
Prestwick2_000479
Prestwick3_000479
Prestwick_661
Proralone-Mop
Proralone-mop
Psoralen-Mop
Psoralen-mop
Psoralon-MOP
Puvalen
Puvamet
S1952_Selleck
SAM002548974
SDCCGMLS-0042377.P002
SMR000071170
SPBio_001004
SPBio_002557
SPECTRUM1500400
STK735539
STOCK1N-03091
Sanofi Synthelabo Brand of Methoxsalen
Sanofi-Synthelabo Brand of Methoxsalen
Spectrum2_001052
Spectrum3_000499
Spectrum4_000052
Spectrum5_001891
Spectrum_001023
UNII-U4VJ29L7BQ
Ultra Mop
Ultra mop
Ultramop
Ultramop Lotion
Uvadex
WLN: T C566 DO LVOJ BO1
X0009
XANTHOTOXIN
Xanthotoxin
Xanthotoxine
Xanthoxin
ZINC02548959
Zanthotoxin
an 8-methoxyfurocoumarin
methoxsalen
5
Bexaroteneapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1, Phase 043153559-49-082146
Synonyms:
153559-49-0
3-methyl-TTNEB
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid
4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid
9RA
AC1L32UG
BIDD:PXR0021
Bexaroten
Bexarotene
Bexarotene (USAN/INN)
Bexarotene [USAN]
Bexaroteno
Bexarotenum
Bexarotène
C095105
CHEBI:50859
CHEMBL1023
CID82146
D03106
DB00307
Elan brand of bexarotene
 
HMS2089L14
HSDB 7453
I14-1941
LG 1069
LG-100069
LG100069
LG1069
LG69 compound
LGD 1069
LGD-1069
LGD1069
LS-38306
Ligand brand of bexarotene
MolPort-003-845-030
NCGC00181016-01
P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
SBB067189
Targret
Targretin
Targretin (TN)
Targretin-gel
Targretyn
Targrexin
UNII-A61RXM4375
bexaroteno
bexarotenum
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid
6
Denileukin diftitoxapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 148173146-27-5
Synonyms:
DT
Diphtheria toxin precursor
 
NAD(+--diphthamide ADP- ribosyltransferase)
Ontak
denileukin diftitox
7
FosaprepitantapprovedPhase 4154172673-20-0219090
Synonyms:
Fosaprepitant dimeglumine
 
Fosaprepitantum
L-758,298
L-758298
8
Folic Acidapproved, nutraceuticalPhase 4, Phase 3, Phase 2, Phase 1, Phase 0292459-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
9
substance PinvestigationalPhase 421733507-63-036511, 44359816
Synonyms:
 
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2
10Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 03836
11Vitamin B ComplexPhase 4, Phase 3, Phase 2, Phase 1, Phase 02847
12AntiemeticsPhase 4, Phase 3, Phase 2, Phase 13213
13Photosensitizing AgentsPhase 4, Phase 3, Phase 2, Phase 1374
14Neurokinin-1 Receptor AntagonistsPhase 4185
15Histone Deacetylase InhibitorsPhase 4, Phase 2, Phase 3, Phase 1532
16Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 118510
17Neurotransmitter AgentsPhase 4, Phase 3, Phase 2, Phase 114795
18interferonsPhase 4, Phase 2, Phase 11930
19Gastrointestinal AgentsPhase 4, Phase 3, Phase 2, Phase 16401
20neurokinin APhase 4220
21Antimetabolites, AntineoplasticPhase 4, Phase 3, Phase 2, Phase 15770
22Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 08496
23Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 017220
24Pharmaceutical SolutionsPhase 4, Phase 2, Phase 17004
25Interferon-alphaPhase 4, Phase 21028
26Protective AgentsPhase 4, Phase 3, Phase 1, Phase 2, Phase 05651
27Antiviral AgentsPhase 4, Phase 3, Phase 2, Phase 18071
28AntimetabolitesPhase 4, Phase 3, Phase 2, Phase 19454
29Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 1, Phase 018483
30Folic Acid AntagonistsPhase 4, Phase 3, Phase 2, Phase 1, Phase 01643
31Dermatologic AgentsPhase 4, Phase 3, Phase 2, Phase 14555
32Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Phase 010422
33Clorazepate DipotassiumPhase 43
34Vitamin B9NutraceuticalPhase 4, Phase 3, Phase 2, Phase 1, Phase 02924
35Folinic AcidNutraceuticalPhase 4, Phase 3, Phase 2, Phase 1, Phase 02604
36FolateNutraceuticalPhase 4, Phase 3, Phase 2, Phase 1, Phase 02924
37
Miconazoleapproved, investigationalPhase 3, Phase 1, Phase 2302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
38
Busulfanapproved, investigationalPhase 2, Phase 3, Phase 1, Phase 050655-98-12478
Synonyms:
1, 4-Dimethanesulfonoxybutane
1, 4-Dimethylsulfonoxybutane
1, {4-Bis[methanesulfonoxy]butane}
1,4-BUTANEDIOL DIMETHANESULFONATE
1,4-Bis(methanesulfonoxy)butane
1,4-Bis(methanesulfonyloxy)butane
1,4-Bis[methanesulfonoxy]butane
1,4-Butanedi yl dimethanesulfonate
1,4-Butanediol dimethanesulfonate
1,4-Butanediol dimethanesulphonate
1,4-Butanediol dimethylsulfonate
1,4-Butanediol, dimethanesulfonate
1,4-Butanediol, dimethanesulphonate
1,4-Butanediyl dimethanesulfonate
1,4-Di(methylsulfonoxy)butane
1,4-Dimesyloxybutane
1,4-Dimethane sulfonyl oxybutane
1,4-Dimethanesulfonoxybutane
1,4-Dimethanesulfonoxylbutane
1,4-Dimethanesulfonyloxybutane
1,4-Dimethanesulphonyloxybutane
1,4-Dimethylsulfonoxybutane
1,4-Dimethylsulfonyloxybutane
2041 C. B
2041 C. B.
2041 C.B
2041 C.B.
4-((Methylsulfonyl)oxy)butyl methanesulfonate
4-methylsulfonyloxybutyl methanesulfonate
55-98-1
AC-198
AC1L1DRQ
AC1Q4GRQ
AI3-25012
AKOS003614975
AN 33501
Ambap55-98-1
B1022
B2635_FLUKA
B2635_SIGMA
BRN 1791786
BSPBio_001920
BUSULFAN (1,4-BUTANEDIOL, DIMETHANESULFONATE)
Bisulfex
Busilvex
Busulfan
Busulfan (JP15/USP/INN)
Busulfan GlaxoSmithKline Brand
Busulfan Orphan Brand
Busulfan Wellcome
Busulfan Wellcome Brand
Busulfan [INN:JAN]
Busulfano
Busulfano [INN-Spanish]
Busulfanum
Busulfanum [INN-Latin]
Busulfex
Busulphan
Busulphane
Butanedioldimethanesulfonate
Buzulfan
C.B. 2041
C6H14O6S2
CB 2041
CCRIS 418
CHEBI:28901
CHEMBL820
CID2478
CPD000058613
Citosulfan
D002066
D00248
DB01008
DivK1c_000847
EINECS 200-250-2
FT-0083567
G.T. 41
GT 2041
GT 41
Glaxo Wellcome Brand of Busulfan
GlaxoSmithKline Brand of Busulfan
Glyzophrol
HMS1920I07
HMS2091O09
HMS502K09
 
HSDB 7605
I09-1371
IDI1_000847
InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3
KBio1_000847
KBio2_000512
KBio2_003080
KBio2_005648
KBio3_001420
KBioGR_000698
KBioSS_000512
LS-1358
Leucosulfan
MLS001076666
MYLERAN (TN)
Mablin
Methanesulfonic
Methanesulfonic acid, tetram ethylene ester
Methanesulfonic acid, tetramethylene ester
Mielevcin
Mielosan
Mielucin
Milecitan
Mileran
Misulban
Mitosan
Mitostan
MolPort-001-783-406
Myeleukon
Myeloleukon
Myelosan
Myelosanum
Mylecytan
Myleran
Myleran Tablets
Myleran tablets
Myleran, Busulfex, Busulfan
Mylerlan
NCGC00090905-01
NCGC00090905-02
NCGC00090905-03
NCGC00090905-04
NCGC00090905-05
NCGC00090905-06
NCGC00090905-07
NCI-C01592
NCI60_041640
NCIMech_000192
NINDS_000847
NSC 750
NSC-750
NSC-750sulphabutin
NSC750
Orphan Brand of Busulfan
Prestwick_989
S1692_Selleck
SAM002554887
SMR000058613
SPBio_000253
SPECTRUM1500152
ST50825921
Spectrum2_000067
Spectrum3_000320
Spectrum4_000259
Spectrum5_000928
Spectrum_000092
Sulfabutin
Sulfabutin (VAN)
Sulphabutin
Tetramethylene Dimethane Sulfonate
Tetramethylene bis(methanesulfonate)
Tetramethylene bis[methanesulfonate]
Tetramethylene dimethane sulfonate
Tetramethylene {bis[methanesulfonate]}
Tetramethylenester Kyseliny Methansulfonove
Tetramethylenester kyseliny methansulfonove
Tetramethylenester kyseliny methansulfonove [Czech]
UNII-G1LN9045DK
WLN: WS1&O4OSW1
Wellcome Brand of Busulfan
Wellcome, Busulfan
X 149
acid, tetramethylene ester
alkylating agent: crosslinks guanine residues
busulfan
butane-1,4-diyl dimethanesulfonate
n-Butane-1,3-di(methylsulfonate)
39
EtoposideapprovedPhase 2, Phase 3, Phase 1, Phase 0116933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
 
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide Phosphate
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
40
FludarabineapprovedPhase 2, Phase 3, Phase 1105921679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-Fluoro-ara AMP
2-Fluoroadenine arabinoside 5'-monophosphate
21679-14-1
2F-Ara-AMP
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
 
Fludara, Fludarabine
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine Phosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
Oforta
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
41
CarboplatinapprovedPhase 2, Phase 3, Phase 1188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
42
Amphotericin Bapproved, investigationalPhase 31171397-89-314956, 5280965
Synonyms:
12633-72-6
1397-89-3
30782-62-8
5-18-10-00525 (Beilstein Handbook Reference)
54482-28-9
8055-20-7
AB00513832
ABLC
AC1L1CN2
AC1L24V6
AC1L70KF
AC1L73U6
AC1NQXTD
AC1NTQ32
AC1NUQG4
AC1NY9JC
AC1O7GCZ
AC1O8FQV
AC1O8PFK
AI3-26528
AMPH-B
AMPH-b
Abelcet
Abelecet
AmBisome (TN)
Ambap1397-89-3
Ambisome
Amfotericina B
Amfotericina B [INN-Spanish]
Ampho-Moronal
Amphocin
Amphomoronal
Amphortericin B
Amphotec
Amphotec (TN)
Amphotericin
Amphotericin .BETA.
Amphotericin B
Amphotericin B (JP15/USP/INN)
Amphotericin B Cholesterol Dispersion
Amphotericin B Cholesteryl Sulfate Complex
Amphotericin B Colloidal Dispersion
Amphotericin B [USAN:INN:JAN]
Amphotericin B, Lipid-based
Amphotericin B, Streptomyces sp.
Amphotericin-B
Amphotericine B
Amphotericine B [INN-French]
Amphotericinum
Amphotericinum B
Amphotericinum B [INN-Latin]
Amphotherizin
Amphotherizin [German]
Amphotéricine B
Amphozone
BIDD:GT0351
BPBio1_000374
BRN 0078342
BSPBio_000340
C-AmB
C06573
C47H73NO17
CCRIS 5963
CHEBI:2682
CHEMBL1200646
CHEMBL267345
CID10533925
CID10629638
CID10677275
CID14956
 
CID1972
CID352546
CID354192
CID5280965
CID5386092
CID5458486
CID5771695
CID6604295
CID6708817
CID6713692
CID9919339
D00203
DB00681
DivK1c_007045
EINECS 215-742-2
Fungilin
Fungisome
Fungisone
Fungizone
Fungizone (TN)
HMS1569A22
HSDB 3008
HSDB 3008 IAB
Halizon
I06-0257
KBio1_001989
KBio2_000551
KBio2_003119
KBio2_005687
KBioGR_002298
KBioSS_000551
LMPK06000002
LNS-AmB
LS-187721
LS-93
Liposomal Amphotericin B
Liposomal amphotericin b
MLS002702966
MolPort-006-392-260
Mysteclin-F
NCGC00014913
NCGC00090808-01
NCGC00098014-01
NCGC00179595-01
NCI527017
NCI60_004288
NCIStruc1_001042
NCIStruc2_000920
NKTR-024
NS 718
NSC 527017
NSC-527017
NSC527017
Prestwick0_000410
Prestwick1_000410
Prestwick2_000410
Prestwick3_000410
Prestwick_721
SMP1_000302
SMR001566780
SPBio_000715
SPBio_002279
ST50999656
SinuNase
SpecPlus_000949
Spectrum2_000818
Spectrum4_001779
Spectrum_000111
UNII-7XU7A7DROE
amophotericin B
amphotericin B liposomal
amphotericin b
43
Epoetin alfaapprovedPhase 3, Phase 2626113427-24-0
Synonyms:
Epogen
 
Erythropoietin precursor
Procrit
44
CefepimeapprovedPhase 3, Phase 13388040-23-75479537
Synonyms:
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime)
7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate
88040-23-7
AC1NUIFH
Axepim
BMY 28142
BMY-28142
C08111
C19H24N6O5S2
CFPM
CHEBI:478164
CHEMBL186
CID5479537
Cefepima
Cefepima [Spanish]
Cefepima [spanish]
 
Cefepime
Cefepime (USAN/INN)
Cefepime Hydrochloride
Cefepime [USAN:INN]
Cefepime dihydrochloride monohydrate
Cefepime hydrochloride
Cefepimum
Cefepimum [Latin]
Cefepimum [latin]
Cepimax
Cepimex
D02376
DB01413
HMS2089M18
LS-178033
Maxcef
Maxipime
UNII-807PW4VQE3
ZINC03871924
cefepime
45
ThiotepaapprovedPhase 2, Phase 3, Phase 120552-24-45453
Synonyms:
 
Thioplex
46
MelphalanapprovedPhase 2, Phase 3, Phase 1685148-82-34053, 460612
Synonyms:
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
148-82-3
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3025 C.B.
3025 c.b
3223-07-2
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
AC1LA2OE
ALKERAN (TN)
AY3360000
Alanine Nitrogen Mustard
Alkeran
AmbotzHAA1563
At-290
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
L-PAM
L-Phenylalanine mustard
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
LS-15868
LS-865
Levofalan
 
Levofolan
Levopholan
M2011_SIGMA
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
MLS001333666
MLS002153368
Melfalan
Melfalano
Melfalano [INN-Spanish]
Melphalan (JP15/USP/INN)
Melphalan Hydrochloride
Melphalan [USAN:INN:BAN:JAN]
Melphalan hydrochloride
Melphalanum
Melphalanum [INN-Latin]
Mephalan
MolPort-003-665-535
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC-8806
NSC241286
NSC8806
P-Di-(2-chloroethyl)amino-L-phenylalanine
P-L-Sarcolysin
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
SPECTRUM1500382
Sarcolysine
Sarkolysin
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
Spectrum_000397
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
melphalan
p-Bis(beta-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
p-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Di(chloroethyl)aminophenylalanine
p-N-di(chloroethyl)aminophenylala nine
phenylalanine nitrogen mu stard
47
CaspofunginapprovedPhase 3, Phase 261179463-17-3, 162808-62-0468682, 2826718
Synonyms:
(4R,5S)-5-((2-Aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(P-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
(4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
(4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin b0
1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0
162808-62-0
AC1L45LR
AC1LAHR5
AC1MCVUN
AR-1K4318
CASPO
CHEBI:474180
CHEMBL374999
CHEMBL499808
CID151068
CID2826718
CID468682
Cancidas
Cancidas (TM)
 
Cancidas (TN)
Capsofungin
Caspofungin
Caspofungin (INN)
Caspofungin [INN]
Caspofungin acetate
D07626
DB00520
HSDB 7476
L-743,872
LS-186994
LS-187303
LS-187635
M991
MK-0991
N-{(2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-12-[(2-aminoethyl)amino]-20-[(1R)-3-amino-1-hydroxypropyl]-23-[(1S2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide
Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]- (9CI)
UNII-F0XDI6ZL63
[1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate
n-{(2r,6s,9s,11r,12s,14as,15s,20s,23s,25as)-12-[(2-aminoethyl)amino]-20-[(1r)-3-amino-1-hydroxypropyl]-23-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1r)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide
nchembio.184-comp7
48
CaptoprilapprovedPhase 32962571-86-244093
Synonyms:
(2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline
(2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
(S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline
(S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline
1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline
1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline
1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S)
1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
1j37
3-Mercapto-2-methylpropionyl-proline
62571-86-2
AC-12047
AC1L2B4L
AC1Q29GZ
AC1Q5R48
Acediur
Aceplus
Acepress
Acepril
Alopresin
Apopril
Apopril (TN)
Asisten
BB_NC-2104
BIM-0050290.0001
BPBio1_000063
BRD-K54529596-001-04-0
BSPBio_000057
BSPBio_002976
C 4042
C4042_SIAL
C4042_SIGMA
C8856_SIAL
C9H15NO3S
CHEBI:3380
CHEMBL1560
CHEMBL82
CID44093
CP
CPD0-2067
CPD000059061
Capoten
Capoten (TN)
Captolane
Captopril
Captopril (JP15/USP/INN)
Captopril [USAN:INN:BAN:JAN]
Captoprilum
Captoprilum [INN-Latin]
Captopryl
Captoril
Captril
Cesplon
D-2-Methyl-3-mercaptopropanoyl-L-proline
D-3-Mercapto-2-methylpropanoyl-L-proline
D-3-Mercapto-2-methylpropionylproline
D00251
DB01197
Dilabar
DivK1c_000208
EINECS 263-607-1
EU-0100302
FT-0082749
Garranil
Garranil (discontinued)
HMS1921C12
 
HMS2089P19
HMS2092I12
HMS500K10
HSDB 6527
Hipertil
Hypertil
IDI1_000208
Isopresol
KBio1_000208
KBio2_001168
KBio2_003736
KBio2_006304
KBio3_002196
KBioGR_001321
KBioSS_001168
L-Captopril
LS-137465
Lopac-C-4042
Lopac0_000302
Lopirin
Lopirin [Switzerland]
Lopril
MCO
MLS000069484
MLS001076488
MolPort-001-794-639
N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline
NCGC00015235-01
NCGC00015235-02
NCGC00023654-03
NCGC00023654-04
NCGC00023654-05
NCGC00023654-06
NCGC00023654-07
NCGC00023654-08
NCGC00023654-09
NCGC00023654-10
NINDS_000208
Prestwick3_000019
Prestwick_103
SA 333
SAM002564201
SMP1_000056
SMR000059061
SPBio_001022
SPECTRUM1500682
SQ 14,225
SQ 14225
SQ-14,225
SQ-14,534
SQ-14225
SQ-14534
ST079562
STK802012
Spectrum2_001211
Spectrum3_001388
Spectrum4_000811
Spectrum5_001587
Spectrum_000688
Tenosbon
Tensiomin
Tensobon
Tensoprel
UNII-9G64RSX1XD
UPCMLD-DP003
UPCMLD-DP003:001
X8Z
[2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline
captopril
49
Cyclophosphamideapproved, investigationalPhase 3, Phase 2, Phase 1, Phase 0264350-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
50
Palivizumabapproved, investigationalPhase 324188039-54-5
Synonyms:
188039-54-5
D02737
Palivizumab
Palivizumab (INN)
 
Palivizumab (genetical recombination)
Palivizumab (genetical recombination) (JAN)
Synagis
Synagis (TN)
anti-RSV

Interventional clinical trials:

(show top 50)    (show all 503)
idNameStatusNCT IDPhase
1Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL)CompletedNCT01007448Phase 4
2Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT00211198Phase 4
3Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2ACompletedNCT00221039Phase 4
4Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) PatientsCompletedNCT00050999Phase 4
5Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma PatientsCompletedNCT00051012Phase 4
6Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell LymphomaRecruitingNCT01569724Phase 4
7Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell LymphomasRecruitingNCT02323659Phase 4
8PUVA Versus PUVA + IFN Alpha 2a in Mycosis FungoidesTerminatedNCT00630903Phase 4
9Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary SyndromeTerminatedNCT01625455Phase 4
10Impact of Vorinostat on Pruritus Signaling Pathways - Merck StudyWithdrawnNCT01801670Phase 4
11Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell LymphomaCompletedNCT00425555Phase 2, Phase 3
12Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell LymphomaCompletedNCT00490776Phase 2, Phase 3
13Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or LymphomaCompletedNCT00005590Phase 3
14Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell CountCompletedNCT00003805Phase 3
15Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical TrialCompletedNCT00750009Phase 3
16American Ginseng in Treating Patients With Fatigue Caused by CancerCompletedNCT00719563Phase 3
17Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer PainCompletedNCT00666211Phase 3
18Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With CancerCompletedNCT00661999Phase 3
19Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a CatheterCompletedNCT00006083Phase 3
20St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for CancerCompletedNCT00005805Phase 3
21Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for CancerCompletedNCT00070382Phase 3
22Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer TreatmentCompletedNCT00008359Phase 3
23Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer PatientsCompletedNCT00003938Phase 3
24Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
25Treatment for Chronic Pain in Patients With Advanced CancerCompletedNCT00003687Phase 3
26Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late ComplicationsCompletedNCT00799461Phase 3
27Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With CancerCompletedNCT00053053Phase 3
28Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer TreatmentCompletedNCT00006348Phase 3
29Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other DiseasesCompletedNCT00438958Phase 3
30Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell TransplantCompletedNCT00305851Phase 3
31Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell TransplantationCompletedNCT00014391Phase 3
32Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell TransplantationCompletedNCT00004230Phase 3
33Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow TransplantationCompletedNCT00003883Phase 3
34Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00045292Phase 3
35FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)RecruitingNCT02448381Phase 3
36Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile NeutropeniaRecruitingNCT00445497Phase 3
37Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic PainRecruitingNCT01316744Phase 3
38PUVA Maintenance Therapy in Mycosis FungoidesRecruitingNCT01686594Phase 3
39T Cell Repertoire Analysis of Immune Mediated Skin DiseasesRecruitingNCT00368784Phase 3
40A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell LymphomaActive, not recruitingNCT01578499Phase 3
41A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell LymphomaActive, not recruitingNCT01871727Phase 3
42Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCLActive, not recruitingNCT01728805Phase 3
43Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and NeutropeniaActive, not recruitingNCT00020865Phase 3
44Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic CancerActive, not recruitingNCT00003816Phase 2, Phase 3
45Lenalidomide Maintenance Post-debulking in Advanced CTCLTerminatedNCT01098656Phase 3
46Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's LymphomaTerminatedNCT00060385Phase 2, Phase 3
47Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary SyndromeTerminatedNCT00127881Phase 3
48Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell TransplantTerminatedNCT00324324Phase 3
49Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis FungoidesTerminatedNCT00056056Phase 3
50Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell LymphomaWithdrawnNCT01386398Phase 3

Search NIH Clinical Center for Cutaneous T Cell Lymphoma

Inferred drug relations via UMLS65/NDF-RT43:

Genetic Tests for Cutaneous T Cell Lymphoma

About this section

Anatomical Context for Cutaneous T Cell Lymphoma

About this section

MalaCards organs/tissues related to Cutaneous T Cell Lymphoma:

33
T cells, Bone, Bone marrow, Skin, B cells, Liver, Breast

Animal Models for Cutaneous T Cell Lymphoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Cutaneous T Cell Lymphoma:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053976.5ADA, CCL17, HSD17B11, IFNG, IL15, IL2
2MP:00053876.2ADA, CCL17, HSD17B11, IFNG, IL15, IL2

Publications for Cutaneous T Cell Lymphoma

About this section

Articles related to Cutaneous T Cell Lymphoma:

(show top 50)    (show all 777)
idTitleAuthorsYear
1
Posterolateral lumbar fusion: Relationship between computed tomography Hounsfield units and symptomatic pseudoarthrosis. (26693390)
2015
2
Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. (25645920)
2015
3
Phenotype variations of retinal dystrophies caused by mutations in the RLBP1 gene. (25429852)
2015
4
Partial loss of presenilin impairs age-dependent neuronal survival in the cerebral cortex. (25429133)
2014
5
The Copper Metabolism MURR1 domain protein 1 (COMMD1) modulates the aggregation of misfolded protein species in a client-specific manner. (24691167)
2014
6
Targeting sphingosine kinase 1 attenuates bleomycin-induced pulmonary fibrosis. (23315259)
2013
7
Mandibular distraction in a 75-day-old child with severe Pierre Robin sequence. (23960331)
2013
8
Ocular cysticercosis in a 32-year-old man in Abuja: ultrasonic features as an aid in diagnosis. (24348016)
2013
9
A case of infantile Takayasu arteritis with a p.D382E NOD2 mutation: an unusual phenotype of Blau syndrome/early-onset sarcoidosis? (22821420)
2013
10
Normal pressure hydrocephalus mimicking Alzheimer's disease: such an infrequent case? (23863346)
2013
11
Interocular effect during visual acuity measurement with and without amblyopia. (23713923)
2013
12
Information for parents. Whooping cough (pertussis). (24245438)
2013
13
Antiinflammatory role of MUC1 mucin during infection with nontypeable Haemophilus influenzae. (22298528)
2012
14
Expression of Toll-like receptors 2, 4 and 9 in patients with Guillain-BarrAc syndrome. (22067623)
2012
15
Conserved mechanisms of Mycobacterium marinum pathogenesis within the environmental amoeba Acanthamoeba castellanii. (22247144)
2012
16
Simultaneous combined single stage removal of immature teratoma at anterior skull base: a case report. (22502784)
2012
17
Hypoglycemia associated with the use of levofloxacin. (19451612)
2009
18
Gephyrin oligomerization controls GlyR mobility and synaptic clustering. (19535575)
2009
19
Voriconazole in the treatment of allergic bronchopulmonary aspergillosis in cystic fibrosis. (19284017)
2009
20
Prevalence and clinical significance of auto-antibodies in adults with cystic fibrosis. (19443536)
2009
21
Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. (19238168)
2009
22
Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. (19258477)
2009
23
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. (19901119)
2009
24
Dyschromatosis universalis hereditaria: evidence for autosomal recessive inheritance and identification of a new locus on chromosome 12q21-q23. (18462451)
2008
25
Evaluation of circulating cathodic antigen (CCA) strip for diagnosis of urinary schistosomiasis in Hassoba school children, Afar, Ethiopia. (18416249)
2008
26
Serpin acceleration of amyloid fibril formation: a role for accessory proteins. (17174330)
2007
27
Human gene mutations. Gene symbol: RPS19. Disease: Diamond-Blackfan anaemia. (18386371)
2007
28
BCL10 expression in ocular adnexal lymphomas. (16310461)
2005
29
Trimethoprim-sulfamethoxazole in the treatment of Stenotrophomonas maltophilia osteomyelitis. (15844086)
2005
30
Contribution of capsaicin-sensitive sensory neurons to antithrombin-induced reduction of ischemia/reperfusion-induced liver injury in rats. (15630490)
2005
31
Myoclonus-dystonia due to genomic deletions in the epsilon-sarcoglycan gene. (16240355)
2005
32
Does a thoracic epidural confer any additional benefit following video-assisted thoracoscopic pleurectomy for primary spontaneous pneumothorax? (15784372)
2005
33
Rheumatic fever. (15522676)
2004
34
Clinical and molecular genetics of the human GnRH receptor. (14714589)
2003
35
Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity. (12902325)
2003
36
Protein-losing enteropathy detected on Tc-99m HSA and Tc-99m MDP scintigraphy. (12045436)
2002
37
Transesophageal echocardiographic assessment of coronary stenosis: a decade of experience. (11182783)
2001
38
Preperitoneal lipoleiomyoma of the abdominal wall in a postmenopausal woman. (11099871)
2000
39
Association between the tryptophan hydroxylase gene and manic-depressive illness. (9435758)
1998
40
An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells. (9703910)
1998
41
Expression of the NK-TR gene is required for NK-like activity in human T cells. (8144875)
1994
42
Acute effect of oral, intraperitoneal, and intravenous 1 alpha-hydroxycholecalciferol on markers of bone metabolism. (8090332)
1994
43
Host defence capacities of pulmonary surfactant: evidence for 'non-surfactant' functions of the surfactant system. (7828630)
1994
44
Pulmonary strongyloidiasis. (7063915)
1982
45
Grey-scale ultrasonography and percutaneous transhepatic cholangiography in biliary tract disease. (7437863)
1980
46
Enzymatic determinants of responsiveness of the LPC-1 plasma cell neoplasm to fluorouracil and fluorodeoxyuridine. (4254308)
1970
47
Surgical problems involved in the removal of glomus-jugulare tumors. (13015599)
1951
48
49
50

Variations for Cutaneous T Cell Lymphoma

About this section

Cosmic variations for Cutaneous T Cell Lymphoma:

7
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM532KRAShaematopoietic and lymphoid tissue,skin,lymphoid neoplasm,cutaneous T cell lymphoma1

Expression for genes affiliated with Cutaneous T Cell Lymphoma

About this section
Search GEO for disease gene expression data for Cutaneous T Cell Lymphoma.

Pathways for genes affiliated with Cutaneous T Cell Lymphoma

About this section

Pathways related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 24)
idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.6IFNG, IL2, IL2RA
29.6IFNG, IL2, IL2RA
3
Show member pathways
9.6IFNG, IL2, IL2RA
49.5IFNA2, IFNG, IL2
5
Show member pathways
9.3IFNG, IL2, STAT3
69.3IFNG, IL15, IL2
7
Show member pathways
9.3IFNG, IL2RA, STAT3
89.1CCL17, IFNG, IL2, IL2RA
99.0IFNG, IL2, IL2RA, STAT3
10
Show member pathways
9.0IFNG, IL2, IL2RA, STAT3
11
Show member pathways
9.0IFNG, IL2, IL2RA, STAT3
12
Show member pathways
9.0IFNG, IL15, IL2, IL2RA
138.9IFNA1, IFNA2, IFNG
14
Show member pathways
8.9IFNA1, IFNA2, IFNG
158.7IFNG, IL15, IL2, IL2RA, IL7
168.5IFNA1, IFNA2, IL2, IL2RA, IL7
178.4IFNA2, IFNG, IL15, IL2, IL2RA, IL7
18
Show member pathways
8.2IFNA1, IFNA2, IFNG, IL15, IL2
197.9IFNA1, IFNA2, IFNG, IL2, IL2RA, STAT3
20
Show member pathways
7.4IFNA1, IFNA2, IFNG, IL15, IL2, IL2RA
21
Show member pathways
7.4IFNA1, IFNA2, IFNG, IL15, IL2, IL2RA
22
Show member pathways
7.1IFNA1, IFNA2, IFNG, IL15, IL2, IL2RA
23
Show member pathways
6.6CCL17, IFNA1, IFNA2, IFNG, IL15, IL2
24
Show member pathways
6.4CCL17, HDAC9, IFNA1, IFNA2, IFNG, IL15

GO Terms for genes affiliated with Cutaneous T Cell Lymphoma

About this section

Biological processes related to Cutaneous T Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1regulation of T cell homeostatic proliferationGO:004601310.6IL2, IL2RA
2positive regulation of T cell differentiationGO:004558210.5IL2, IL7
3positive regulation of tissue remodelingGO:003410510.4IL15, IL2
4positive regulation of isotype switching to IgG isotypesGO:004830410.2IFNG, IL2
5negative regulation of inflammatory responseGO:005072810.0ADA, IL2, IL2RA
6T cell activation involved in immune responseGO:000228610.0IFNA1, IFNA2
7regulation of T cell differentiationGO:00455809.7ADA, IL15
8B cell differentiationGO:00301839.6HDAC9, IFNA1, IFNA2
9positive regulation of peptidyl-serine phosphorylation of STAT proteinGO:00331419.6IFNA1, IFNA2, IFNG
10agingGO:00075689.2ADA, IL15, STAT3
11cell-cell signalingGO:00072679.1IFNA2, IL15, IL2, IL7
12defense response to virusGO:00516078.9IFNA1, IFNA2, IFNG
13immune responseGO:00069558.0CCL17, IFNG, IL15, IL2, IL2RA, IL7

Sources for Cutaneous T Cell Lymphoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet